EU consults on future of project for accelerating trials in developing countries
This article was originally published in SRA
Executive Summary
The European Commission is seeking feedback on the future of a research and development programme that was set up to accelerate the development of new and improved drugs against HIV/AIDS, malaria and tuberculosis. The programme’s current focus is on conducting Phase II and III clinical trials in Sub-Saharan Africa1,2.